Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

164.61USD
26 Apr 2017
Change (% chg)

$-0.09 (-0.05%)
Prev Close
$164.70
Open
$165.61
Day's High
$165.61
Day's Low
$164.34
Volume
4,175,536
Avg. Vol
3,658,002
52-wk High
$184.21
52-wk Low
$133.64

Latest Key Developments (Source: Significant Developments)

Amgen optimistic for Enbrel sales rebound
6:21pm EDT 

April 26 (Reuters) - Amgen Inc :Amgen says optimistic about rebound in Enbrel sales in coming quarters after Q1 decline.Amgen says Enbrel will be significant cash flow generator for many years to come.  Full Article

Amgen reports Q1 GAAP earnings per share $2.79
4:04pm EDT 

April 26 (Reuters) - Amgen Inc :Q1 GAAP earnings per share $2.79.Q1 non-GAAP earnings per share $3.15.Q1 revenue down 1 percent to $5.46 billion.Says 2017 earnings per share guidance increased to $10.64-$11.32 on GAAP basis, and $12.00-$12.60 on non-GAAP basis.Says 2017 total revenue guidance unchanged at $22.3 billion to $23.1 billion.Sees 2017 capital expenditures to be about $700 million.Q1 earnings per share view $3.00, revenue view $5.60 billion -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $12.35, revenue view $23.01 billion -- Thomson Reuters I/B/E/S.  Full Article

Amgen reports Q1 non-gaap earnings per share $3.15
4:04pm EDT 

April 26 (Reuters) - Amgen Inc :Amgen reports first quarter 2017 financial results.Q1 revenue fell 1 percent to $5.5 billion.Q1 non-gaap earnings per share $3.15.Q1 gaap earnings per share $2.79.Sees fy 2017 revenue $22.3 billion to $23.1 billion.  Full Article

Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine
Monday, 24 Apr 2017 04:30pm EDT 

April 24 (Reuters) - Amgen Inc ::Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine.Says co, Novartis agreed to combine capabilities to co-commercialize erenumab in U.S.; Amgen retains exclusive commercialization rights in Japan.Says Novartis gains exclusive rights to commercialize erenumab in Canada, retains existing commercialization rights in rest of the world.Says co will receive milestone payments from Novartis expected to begin in 2017; Novartis will share u.s. Commercialization costs with Amgen.Says co will book sales of erenumab in the U.S., and will pay a royalty to Novartis on net sales in the u.s..Says Novartis to book sales in rest of the world (excluding Japan), to pay co royalties on net sales in those countries; co to book sales in Japan.Says Novartis will assume agreed upon remaining global development costs up to a cap and share global development costs thereafter.  Full Article

Amgen submits applications in the U.S. and Europe to expand current indication for xgeva
Tuesday, 4 Apr 2017 09:00am EDT 

Amgen Inc : Amgen submits applications in the us and europe to expand current indication for xgeva® (denosumab) to include patients with multiple myeloma .Amgen Inc - submission of sbla to fda, application for a variation to marketing authorization to ema for xgeva.  Full Article

Amgen enters into agreement with Inovalon and Avalere
Wednesday, 29 Mar 2017 07:55am EDT 

Inovalon Holdings Inc : Amgen enters into agreement with Inovalon and Avalere to engage value-based contracting opportunities . Inovalon Holdings Inc - agreement will focus specifically on Rheumatoid Arthritis (RA) . Inovalon Holdings - Co, Avalere Health will deploy data, analytics capabilities with OBCS to support development of obcs based on value of Amgen's products .Inovalon Holdings - co, Avalere Health, an Inovalon Company, will deploy data, to support further development of OBCS based on value of Amgen's products.  Full Article

European Commission approves Amgevita for treatment of certain inflammatory diseases
Thursday, 23 Mar 2017 04:00pm EDT 

Amgen Inc : European Commission approves Amgevita™ (biosimilar adalimumab) for the treatment of certain inflammatory diseases .Amgen Inc- approval from EC grants a centralized marketing authorization with unified labeling in 28 countries that are members of EU.  Full Article

Amgen Inc reports four-year follow-up results from Repatha Osler-1 study
Tuesday, 14 Mar 2017 04:15pm EDT 

Amgen Inc : Amgen Inc - four-year follow-up results from Repatha (evolocumab) Osler-1 study . Amgen Inc - Repatha, when added to standard of care (SOC), achieved median low-density lipoprotein cholesterol (LDL-C) reductions of 57 percent at four years .Amgen - Repatha, when added to SOC achieved median LDL-C reductions with no new safety concerns identified.  Full Article

Repatha demonstrates reduced need for apheresis in patients with high LDL cholesterol
Monday, 13 Mar 2017 09:00am EDT 

Amgen Inc : Repatha (evolocumab) demonstrates reduced need for apheresis in patients with high LDL cholesterol in phase 3 study . Amgen Inc - no new safety concerns were identified in this study .Amgen - positive top-line results from a phase 3 study evaluating Repatha in patients who were receiving apheresis to reduce low-density lipoprotein cholesterol.  Full Article

Amgen sets quarterly dividend of $1.15 per share
Tuesday, 7 Mar 2017 04:00pm EST 

Amgen Inc :Sets quarterly dividend of $1.15 per share.  Full Article

More From Around the Web

Photo

Cost controls help offset lower Amgen first-quarter drug sales

Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.